Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defensin beta 107A (DEFB107A)
- Target
- DEFB107A
- Molecular classification
- Antimicrobial peptide, Innate immunity effector, Beta-defensin family
01
Overview
Defensin beta 107A is a member of the human beta-defensin family of small cationic peptides involved in the innate immune response[4][1]. This gene encodes a processed peptide secreted by epithelial cells and possibly neutrophils, acting primarily as an antimicrobial effector by disrupting the membranes of invading bacteria, fungi, and some enveloped viruses, thereby leading to pathogen cell lysis[4][1]. Beta-defensins, including DEFB107A, also act as chemoattractants recruiting immune cells to infection sites, contributing to both innate and adaptive immunity[1]. DEFB107A is encoded on chromosome 8p23 and forms part of a gene cluster with paralogs such as DEFB107B[4]. There is no current evidence that this molecule is directly targeted by drugs or used as a disease biomarker; its main importance is as an endogenous antimicrobial and immune modulator[4][1][5].
- Other names
- Defensin, beta 107ABeta-defensin 107ABeta-defensin 107Beta-defensin 7DEFB107DEFB7BD-7DEFB-7Defensin, beta 7DEFB107Adefb107cBD-7defensin, beta 107
02
Biological functions
Antibacterial activity (kills or inhibits growth of Gram-negative and Gram-positive bacteria[4][1])Innate immune response (defense of epithelial barriers against microbial colonization and infection[4][1])Chemotaxis of immune cells (attracts monocytes, T-lymphocytes, dendritic cells, and mast cells to sites of infection[1])Membrane disruption (forms pores in target microbial membranes leading to cell lysis[1][5])Potential enhancement of adaptive immunity (by immune cell recruitment[1])
03
Disease associations
Infection (primary role in host defense against bacterial and possibly some fungal or viral infections[1][4])Other (polymorphisms in beta-defensin genes have been associated in some studies with susceptibility to infection or inflammatory conditions, but there is limited direct evidence for DEFB107A specifically[1])No strong evidence for direct involvement in cancer, neurodegenerative, or cardiovascular diseases.
04
Safety considerations
Potential tissue damage if overexpressed or dysregulated due to nonspecific cytotoxicity of antimicrobial peptides, but not recognized as a specific therapeutic safety issue[1][5].No established therapeutic use; therefore, no specific clinical safety concerns.
Beyond the preview
Go deeper on Defensin beta 107A (DEFB107A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defensin beta 107A (DEFB107A).